SARS-CoV-2 and COVID-19 Research

The paper examines sex differences in the single-cell transcriptome of peripheral blood mononuclear cells after BNT162b2 mRNA vaccination, identifying sexually dimorphic gene expression and immune cell responses.

The paper assesses the neutralization of SARS-CoV-2 Omicron subvariants BA.2.86 and EG.5.1 by antibodies from prior infection or vaccination, finding comparable neutralization titres to XBB.1 and EG.5.1.

This study shows that curcumin and turmeric extract inhibit SARS-CoV-2 pseudovirus entry and cell fusion at specific concentrations.

The paper compares SARS-CoV-2 antigenicity across assays and in human and animal model sera, finding similar immunodominance patterns and antigenic maps but differences in titer magnitude and assay-specific fold change.

This study compares the immune evasion of SARS-CoV-2 Omicron BA.2.86 to XBB sub-variants, finding BA.2.86 shows less neutralization evasion.

The paper shows Omicron SARS-CoV-2 lineages rely on ACE2 without TMPRSS2 complexes for entry, due to changes in the ACE2 Collectrin-Like Domain affecting TMPRSS2 activation.

This paper introduces VirEvol, a platform that predicts and visualizes SARS-CoV-2 evolutionary trends using a protein language model, structural data, and immunological insights, achieving 93% accuracy in identifying high-risk strains.

The paper investigates how multivalent interactions between SARS-CoV-2 spike protein, ACE2 receptor, and patient-derived antibodies influence viral entry and antibody inhibition.

The paper identifies a druggable site on GRP78 at the SARS-CoV-2 interface and screens compounds to disrupt this interaction, potentially leading to new antiviral therapeutics.

This paper identifies a phenothiazine urea derivative that inhibits both SARS-CoV-2 Mpro and PLpro proteases and shows broad antiviral activity against multiple human coronaviruses.

This study uses molecular dynamics simulations to show that the Omicron variant's S477N mutation enhances spike-ACE2 binding, contributing to its higher infectivity compared to Delta.

The paper compares ACE2 gene expression between African-American and non-African-American COVID-19 patients, finding downregulation in African-Americans associated with lower disease severity.

This study develops a modified SARS-CoV-2 spike antigen that enhances cross-neutralization against Omicron subvariants, despite reduced neutralizing potency.

This study characterizes the serological repertoire of SARS-CoV-2 convalescent patients, revealing a high prevalence of iso-RBD antibodies that do not recognize prefusion-stabilized S, and shows that vaccination with prefusion-stabilized S reduces their prevalence.

The paper analyzes SARS-CoV-2 variant BA.2.86 genomes to estimate its emergence date and spread using Bayesian phylogenetics and bioinformatics methods.

The paper identifies meisoindigo as an effective inhibitor of SARS-CoV-2 main protease using a yeast-based screening system.

This study evaluates the neutralization of SARS-CoV-2 EG.5/EG.5.1 by sera from vaccinated individuals and breakthrough infections, finding that next-generation vaccines offer better protection against these variants.

This paper evaluates a subcutaneously administered vaccine targeting the S1 spike protein of SARS-CoV-2 variant C.1.2, showing robust IgG responses and protection against Omicron BA.1 challenge in hamsters.

The paper evaluates the stability of anti-SARS-CoV-2 IgY antibodies at acidic pH and against trypsin digestion, supporting their use in treating viral transmission through acidic environments.

This study shows that Chlorpheniramine Maleate inhibits SARS-CoV-2 by blocking viral adsorption, replication, and direct inactivation through interactions with key viral proteins.

The paper analyzes structural and functional changes in the SARS-CoV-2 XBB sub-lineage Spike protein under African selection pressures, identifying positive selection and recombination in key regions.

This study evaluates the effect of a second BA.5 bivalent booster on SARS-CoV-2 neutralizing antibodies in elderly individuals, finding no significant increase in Omicron-specific titers after the second dose.

The paper models cross-neutralization profiles of SARS-CoV-2 sera against variants by analyzing mutations and shows that a third dose of mRNA-1273 improves neutralization breadth.

The paper analyzes SARS-CoV-2 mutations across 8 million sequences to identify high-mutability proteins and predict surges, providing real-time genomic surveillance.

The paper develops a CNN-LSTM model to classify SARS-CoV-2 variants from spike gene sequences, achieving high accuracy and detecting variants that nextclade missed.

This study analyzes selection pressures in SARS-CoV-1 and SARS-CoV-2 genomes near zoonosis, finding strong purifying selection and limited positive selection, except for NSP12 and ORF7a.

This study shows that a recombinant SARS-CoV-2 virus lacking ORF10 start and internal methionine codons is attenuated in hamsters, with reduced lower respiratory tract viral titre and increased reversion to wild-type.